7-Methyl-1-azabicyclo<2.2.1>heptan | 6457-47-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 7-Methyl-1-azabicyclo<2.2.1>heptan
• 英文别名: 7-methyl-1-aza-norbornane；7-Methyl-1-aza-norbornan；7-Methyl-1-azabicyclo[2.2.1]heptane
• CAS: 6457-47-2
• 化学式: C₇H₁₃N
• 分子量: 111.187
• InChiKey: NOFYMULKSNEAHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢溴酸 、 溶剂黄146 作用下， 生成 7-Methyl-1-azabicyclo<2.2.1>heptan
  参考文献：
  名称：

  Lukes; Ferles, Collection of Czechoslovak Chemical Communications, 1955, vol. 20, p. 1227,1232

  摘要：

  DOI：

文献信息

• Preparation of Quinuclidines¹
  作者：S. Wawzonek、M. F. Nelson、P. J. Thelen

  DOI：10.1021/ja01150a111

  日期：1951.6
• Wawzonek; Wilkinson, Journal of Organic Chemistry, 1966, vol. 31, p. 1732,1734
  作者：Wawzonek、Wilkinson

  DOI：——

  日期：——
• Prelog et al., Collection of Czechoslovak Chemical Communications, 1938, vol. 10, p. 399,409
  作者：Prelog et al.

  DOI：——

  日期：——
• Compositions useful for treating gastrointestinal motility disorders
  申请人：Landau Steven B.

  公开号：US20090048287A1

  公开（公告）日：2009-02-19

  The present invention relates to method of treating a gastrointestinal motility disorder in a subject in need of treatment comprising coadministering to said subject a first amount of a compound having 5-HT 3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof; and a second amount of at least one gastric acid suppressing agent (e.g., a proton pump inhibitor, an H 2 receptor antagonist or a pharmaceutically acceptable salt, hydrate or solvate thereof; or an acid pump antagonist or pharmaceutically acceptable salt, hydrate or solvate thereof) wherein the first and second amounts together comprise a therapeutically effective amount. In particular, the method is for treating GERD, including nocturnal GERD. The invention further relates to a method of treating nocturnal GERD comprising administering to a subject in need thereof a therapeutically effective amount of a compound having 5-HT 3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The invention further relates to a method of increasing esophageal motility in a subject in need thereof. The method of increasing esophageal motility can be achieved by administration of a compound having 5-HT 3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The coadministration can also be used to increase esophageal motility.
• US4292190A
  申请人：——

  公开号：US4292190A

  公开（公告）日：1981-09-29